Clinical Research Directory

Safety of Topical Exosome-Containing Liquid in Healthy Volunteers

This Phase 1 split-site pilot study will evaluate the safety and dermal tolerability of a topical exosome-containing liquid in 10 healthy adult volunteers. The investigational liquid will be applied to a small defined area of intact skin. A vehicle liquid without exosomes may be applied to a matched contralateral skin site as a control. The study will assess local skin reactions, systemic adverse events, vital signs, clinical laboratory parameters, and feasibility of topical administration. No burn wound or artificial skin wound will be induced in participants in this Phase 1 safety study.

Apple Peptide Complex for Post-Surgical and Aesthetic Skin Recovery

This clinical study evaluates a topical botanical formulation for supporting skin recovery following invasive and non-invasive aesthetic procedures. These procedures include liposuction, breast augmentation, Brazilian butt lift (BBL), laser treatments, and micro needling, pregnancy stretch mark and weight loss skin. The study will assess the effects of the formulation on skin elasticity, hydration, and overall appearance when used as part of post-procedure care under the supervision of licensed medical professionals. Participants will apply the product to treatment areas over a defined study period, and outcomes will be compared to a control group receiving standard care or placebo.

Safety of Topical Exosome-Containing Liquid in Healthy Volunteers for Future Surgical Wound Use

This Phase 1 split-site pilot study will evaluate the safety and dermal tolerability of a topical exosome-containing liquid in 10 healthy adult volunteers. The investigational liquid will be applied to a small defined area of intact skin. A vehicle liquid without exosomes may be applied to a matched contralateral skin site as a control. The study will assess local skin reactions, systemic adverse events, vital signs, clinical laboratory parameters, and feasibility of topical administration. No melanoma lesion, surgical wound, burn wound, or artificial skin wound will be induced in participants in this Phase 1 safety study.